Woo KI, Kim YD, Lee SL (2008) The clinical characteristics of thyroid orbitopathy in thyroid dysfunction patients in korea. J Korean Ophthalmol Soc 49:1387–1396. https://doi.org/10.3341/jkos.2008.49.9.1387

Article  Google Scholar 

Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560. https://doi.org/10.1136/bmj.b560

Article  PubMed  Google Scholar 

Woo KI, Kim YD, Lee SY (2013) Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients. Korean J Ophthalmol 27:397–404. https://doi.org/10.3341/kjo.2013.27.6.397

Article  PubMed  PubMed Central  Google Scholar 

Crisp M, Starkey KJ, Lane C, Ham J, Ludgate M (2000) Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41:3249–3255

CAS  PubMed  Google Scholar 

Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D (2016) Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 100:142–150. https://doi.org/10.1136/bjophthalmol-2015-307399

Article  PubMed  Google Scholar 

Shan SJ, Douglas RS (2014) The pathophysiology of thyroid eye disease. J Neuroophthalmol 34:177–185. https://doi.org/10.1097/WNO.0000000000000132

Article  PubMed  Google Scholar 

Douglas RS, Gupta S (2011) The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 22:385–390. https://doi.org/10.1097/ICU.0b013e3283499446

Article  PubMed  PubMed Central  Google Scholar 

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves Orbitopathy (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 5:9–26. https://doi.org/10.1159/000443828

Article  CAS  Google Scholar 

Kumari R, Chandra Saha B (2018) Advances in the management of thyroid eye diseases: an overview. Int Ophthalmol 38:2247–2255. https://doi.org/10.1007/s10792-017-0694-0

Article  PubMed  Google Scholar 

Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodriguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espana Gregori E, Sales-Sanz M, Tocilizumab in Graves Orbitopathy Study Group (2018) Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol 195:181–190. https://doi.org/10.1016/j.ajo.2018.07.038

Article  CAS  Google Scholar 

Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS (2010) Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol 55:215–226. https://doi.org/10.1016/j.survophthal.2009.06.009

Article  PubMed  PubMed Central  Google Scholar 

Copperman T, Idowu OO, Kersten RC, Vagefi MR (2019) Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg 35:e64–e66. https://doi.org/10.1097/IOP.0000000000001346

Article  PubMed  Google Scholar 

Smith TJ (2020) Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy. Best Pract Res Clin Endocrinol Metab 34:101383. https://doi.org/10.1016/j.beem.2020.101383

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC (2014) Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthalmic Plast Reconstr Surg 30:162–167. https://doi.org/10.1097/IOP.0000000000000037

Article  PubMed  Google Scholar 

Kahaly GJ (2019) Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes 26:250–255. https://doi.org/10.1097/MED.0000000000000493

Article  CAS  PubMed  Google Scholar 

Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320–332. https://doi.org/10.1210/jc.2010-1962

Article  CAS  PubMed  Google Scholar 

Ceballos-Macias Jose J, Rivera-Moscoso R, Flores-Real Jorge A, Vargas-Sanchez J, Ortega-Gutierrez G, Madriz-Prado R, Velasco-Ramos PC, Munoz-Monroy Omar E, Meneses-Perez Anna C, Fernandez-Morales Irma N, Hernandez-Moreno A (2020) Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. Ann Endocrinol (Paris) 81:78–82. https://doi.org/10.1016/j.ando.2020.01.003

Article  PubMed  Google Scholar 

Bothun ED, Scheurer RA, Harrison AR, Lee MS (2009) Update on thyroid eye disease and management. Clin Ophthalmol 3:543–551. https://doi.org/10.2147/opth.s5228

Article  PubMed  PubMed Central  Google Scholar 

Verity DH, Rose GE (2013) Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond) 27:308–319. https://doi.org/10.1038/eye.2012.284

Article  CAS  PubMed  Google Scholar 

Sanchez-Bilbao L, Martinez-Lopez D, Revenga M, Lopez-Vazquez A, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodriguez-Mendez V, Garcia-Aparicio A, Veroz-Gonzalez R, Jovani V, Peiteado D, Sanchez-Orgaz M, Tomero E, Toyos-Saenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora A, Conesa A, Fernandez-Prada M, Troyano JA, Calvo-Rio V, Demetrio-Pablo R, Gonzalez-Mazon I, Hernandez JL, Castaneda S, Gonzalez-Gay MA, Blanco R (2020) Anti-IL-6 receptor tocilizumab in refractory graves’ orbitopathy: national multicenter observational study of 48 patients. J Clin Med 9:2816. https://doi.org/10.3390/jcm9092816

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sy A, Eliasieh K, Silkiss RZ (2017) Clinical response to tocilizumab in severe thyroid eye disease. Ophthalmic Plast Reconstr Surg 33:e55–e57. https://doi.org/10.1097/IOP.0000000000000730

Article  PubMed  Google Scholar 

Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marino M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352. https://doi.org/10.1056/NEJMoa1910434

Article  CAS  PubMed  Google Scholar 

Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761. https://doi.org/10.1056/NEJMoa1614949

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (Actemra). Hum Vaccin Immunother 13:1972–1988. https://doi.org/10.1080/21645515.2017.1316909

Article  PubMed  PubMed Central  Google Scholar 

Singh JA, Beg S, Lopez-Olivo MA (2010) Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008331.pub2

Article  PubMed  PubMed Central  Google Scholar 

Biggioggero M, Crotti C, Becciolini A, Favalli EG (2019) Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 13:57–70. https://doi.org/10.2147/DDDT.S150580

Article  CAS  PubMed  Google Scholar 

Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77:1865–1879. https://doi.org/10.1007/s40265-017-0829-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, Stan MN (2023) Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease. Thyroid 33:1237–1244. https://doi.org/10.1089/thy.2023.0167

Article  CAS  PubMed  Google Scholar 

Stan MN, Garrity JA, Bahn RS (2012) The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 96:311–328. https://doi.org/10.1016/j.mcna.2012.01.014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470. https://doi.org/10.1210/jc.2005-2813

Article  CAS  PubMed  Google Scholar 

Monteiro ML, Goncalves AC, Silva CT, Moura JP, Ribeiro CS, Gebrim EM (2008) Diagnostic ability of barrett’s index to detect dysthyroid optic neuropathy using multidetector computed tomography. Clinics (Sao Paulo) 63:301–306. https://doi.org/10.1590/s1807-59322008000300003

Article  PubMed  Google Scholar 

Barrett L, Glatt HJ, Burde RM, Gado MH (1988) Optic nerve dysfunction in thyroid eye disease: CT. Radiology 167:503–507. https://doi.org/10.1148/radiology.167.2.3357962

Article  CAS  PubMed  Google Scholar 

Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861–1874. https://doi.org/10.1016/S0140-6736(07)60784-3

Article  CAS  PubMed  Google Scholar 

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, Investigators O (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997.